

Area Prescribing Group report

Date: Friday 07 March 2025 **Quorate:** Yes

The items in this report are supported by the Cheshire and Merseyside Area Prescribing Group (APG) and approval by NHS Cheshire and Merseyside Integrated Care Board (ICB) is detailed below.

All document links provided for any CMAPG recommendations, can be found via the [legacy Pan Mersey formulary](#). The [legacy Cheshire formulary](#) will also be updated to reflect these changes.

Please note that the legacy Pan Mersey APC website will close on 31/03/2025.

All legacy Pan Mersey APC documents will be available from 01/04/2025 by using the search function on the [legacy Pan Mersey formulary](#), until harmonisation concludes.

CMAPG governance documents are hosted on the [Prescribing](#) section of the NHS Cheshire and Merseyside website.

New medicines

Proposal	Notes	Approval
Lanreotide for angioectasia RAG designation: Red APG subgroup: 14 February 2025 APG: 07 March 2025	<p>This is a new, harmonised red statement for the off-label use of lanreotide in angioectasia. Lanreotide should only be initiated when all other treatment options have been exhausted and should reduce the need for multiple transfusions.</p> <p>Patient numbers across Cheshire and Merseyside are expected to be low, estimated as fewer than 20 patients per year. Lanreotide was already approved for use in Merseyside and the additional cost of implementing in</p>	<p>ICB Medicines Optimisation and Pharmacy (MOP) Group: 20 March 2025, clinically supported by MOP group.</p> <p>ICS Chief Pharmacist: 20 March 2025, approved by ICS Chief Pharmacist</p>

Proposal	Notes	Approval
	Cheshire is £97,450 per year. Submission of Blueteq forms will be required where Blueteq is implemented.	

Formulary and guidelines

Proposal	Notes	Approval
<p>Transanal irrigation in bowel dysfunction</p> <p>RAG designation: Amber initiated</p> <p>APG subgroup: 18 Feb 2025</p> <p>APG: 07 Mar 2025</p>	<p>Transanal irrigation (TAI) was previously going to be incorporated into the Clinical Commissioning Policy workstream. However, no further work on that policy is being conducted and so this has moved to APG responsibility. This amber initiated statement has been developed based on the original commissioning policy content but provides further information to support primary care prescribing.</p> <p>A significant issue identified by consultation concerns the different level of service provision within provider Trusts for TAI, due to differences in resourcing and commissioning positions across Places. The Subgroup view was that the statement should recommend best clinical practice, but it wanted to highlight that currently this may not be possible and this would need to be resolved by changes to commissioning arrangements where necessary.</p> <p>Supported by NICE Medical technologies guidance: MTG36, 23 February 2018 Last updated: 06 June 2022 and PrescQIPP Bulletin, Transanal irrigation, Jan. 2025</p> <p>Expected cost per 100,000 population is £70,800. (£1.9million annually total C&M-wide). Currently the cost is £2.1million annually. NICE states that cost modelling shows it is likely that Peristeen Plus provides additional</p>	<p>ICB Medicines Optimisation and Pharmacy (MOP) Group: 20 March 2025, approved by MOP group.</p>

Proposal	Notes	Approval
	clinical benefits without costing more than standard bowel care. Savings are likely from fewer hospital visits, fewer healthcare professional visits, less carer time, reduced faecal incontinence leading to fewer incontinence pads and fewer urinary tract infections.	
<p>Plenadren (hydrocortisone 5mg and 20mg modified-release tablet) in adrenal insufficiency</p> <p>RAG designation: Amber retained.</p> <p>APG subgroup: 18 Feb 2025</p> <p>APG: 07 Mar 2025</p>	<p>Addition of Plenadren brand of hydrocortisone modified release tablets 5mg, 20mg to the formulary for primary, secondary and tertiary adrenal insufficiency in adults, and in children and young people. Recommended by NICE NG243 August 2024 'Adrenal insufficiency: identification and management' as an alternative glucocorticoid for adults and young people over 12 years with adrenal insufficiency if there are concerns with adherence or if immediate-release hydrocortisone or prednisolone are unsuitable.</p> <p>This would increase expenditure from current £40,000 per annum to £102,000 - £210,000 in Cheshire and Merseyside.</p>	<p>ICB Medicines Optimisation and Pharmacy (MOP) Group: 20 March 2025, clinically supported by MOP group.</p> <p>ICB Medical Director: 25 March 2025, approved by ICB Executive Medical Director.</p>

APG reports

Title	Notes	Approval
<p>NICE TA adherence checklist</p> <p>January 2025</p>	For noting.	<p>ICB Medicines Optimisation and Pharmacy (MOP) Group: 20 March 2025, noted by MOP group.</p>